Clinical trials: Carcinoma, Non-Small-Cell Lung Cancer
Biomarkers
Investigation on Predictive Molecular Markers of Efficacy for Front-line Immunochemotherapy in Advanced NSCLC
This project is a real-world exploratory study aiming to explore potential molecular markers detectable at baseline that can enable the prediction of clinical efficacy of front-line immunotherapy combined with chemotherapy in…
- Trial name
- NCT04858828
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhou Chengzhi
Non-small Cell Lung Cancer
Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine whether Endostar pumping into vein with Gemcitabine-Cisplatin are more effective than Endostar with Gemcitabine-Cisplatin regularly in the treatment of Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT01669707
- Testing
- Endostar -Continued Pumping into+GP, Endostar -injecting into +GP
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Chest Hospital
Non-small Cell Lung Cancer, Radiation Toxicity
Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy
Despite the growing interest in investigating how the radiotherapy (RT) dose to anatomical substructures of the heart links to survival, the heart substructures at risk remain poorly defined.
- Conditions
- Non-small Cell Lung Cancer, Radiation Toxicity, Cardiac Toxicity
- Trial name
- NCT04867564
- Testing
- Echocardiography
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Military Institute od Medicine National Research Institute
Non Small Cell Lung Cancer, ROS1 Proto Oncogene
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
To assess treatment effectiveness and safety of oral crizotinib administered to East Asian patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a ROS1 positive gene mutation…
- Conditions
- Non Small Cell Lung Cancer, ROS1 Proto Oncogene, Crizotinib
- Trial name
- NCT01945021
- Testing
- Crizotinib
- Where
- 44 sites in China, Japan and 2 more
- Volunteers
- 129 people
- Sponsor
- Pfizer
Solid Tumors, Non-small Cell Lung Cancer
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
This is an open-label, multi-center study of Phase Ib/II study to assess the efficacy and safety of Envafolimab combinded with Lenvatinib in the treatment of subjects with advanced solid tumors.
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05024214
- Testing
- Lenvatinib + Envafolimab, Sunitinib
- Where
- 23 sites in China
- Volunteers
- 170 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-IIIB non-small cell lung cancer that cannot be removed by surgery.
- Conditions
- Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage III Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT01993810
- Testing
- Carboplatin, Cisplatin, Durvalumab
- Where
- 30 sites in United States
- Volunteers
- 330 people
- Sponsor
- Radiation Therapy Oncology Group
Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
Investigators plan to study the safety, side effects, and benefits of tumor-infiltrating lymphocytes (TILs) when they are given with the drug nivolumab.
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC
- Trial name
- NCT03215810
- Testing
- Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer
Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer
RET fusions are present in 1% to 2% of unselected population of non-small cell lung cancer (NSCLC). Existing US Food and Drug Administration-approved inhibitors of RET tyrosine kinase show promising therapeutic effects in a…
- Trial name
- NCT02540824
- Testing
- Apatinib single agent arm
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tongji University
Metastatic Nonsmall Cell Lung Cancer
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
This is a Phase I study to evaluate the safety and efficacy of the [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).
- Trial name
- NCT06228482
- Testing
- [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, Davis
Non-Small Cell Lung Cancer (Stage III), Colon Cancer (Stage II &Amp; III)
Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center Programs
Background: -Coordinated cancer care provided by doctors, nurses, social workers, and other care providers is believed to improve patient and physician satisfaction and patient evaluation for enrollment in clinical trials.
- Conditions
- Non-Small Cell Lung Cancer (Stage III), Colon Cancer (Stage II &Amp; III), Rectal Cancer (Stage III)
- Trial name
- NCT01346280
- Where
- United States
- Volunteers
- 1,079 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Analysis of Re-biopsy Specimens in Advanced NSCLC With Acquired Resistance of EGFR-TKI Targeted Therapy
The objective of the study is to reveal the acquired resistance mechanism of the first and second generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in tissue and plasma using Next Generation…
- Trial name
- NCT03309462
- Testing
- Miseq sequencer
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Advanced Non Small Cell Lung Cancer
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
Background: Non-small cell lung cancer (NSCLC) can be hard to treat and is often fatal. People with NSCLC commonly have changes in the bacteria that populate their lungs. These bacterial changes may aid tumor growth.
- Trial name
- NCT05777603
- Testing
- aerosolized aztreonam, aerosolized vancomycin, pembrolizumab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.
This study is single arm, open label, phase II trial for resectable ALK+ NSCLC. Eligible patients will receive brigatinib after 7-day lead-in 90mg from 4 to 10 weeks. The objective of this study is as follows.
- Trial name
- NCT05361564
- Testing
- Brigatinib
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Yonsei University
NSCLC
Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer
This is a multicenter, open-label, randomised, phase III study of 2 cycles of oral vinorelbine in combination with cisplatin concurrently with radiotherapy randomised to either two more cycles of consolidation therapy with oral…
- Trial name
- NCT00683514
- Testing
- Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)
- Where
- Germany
- Volunteers
- 201 people
- Sponsor
- Pierre Fabre Medicament
Advanced Non-small Cell Lung Cancer
Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation
To compare efficacy and safety of Abivertinib maleate alone versus standard first-line EGFR-TKIs for the treatment of patients with advanced non-small cell lung cancer with sensitive EGFR mutation
- Trial name
- NCT03856697
- Testing
- Abivertinib Maleate Capsules, Gefitinib Tablets
- Where
- China
- Volunteers
- 406 people
- Sponsor
- Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Non Small Cell Lung Cancer Stage
Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18…
- Trial name
- NCT04992780
- Testing
- Hypo-Fractionation, Standard-Fractionation
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Kansas Medical Center
Lung Cancer
Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
This trial is designed to study the role of docetaxel/gemcitabine, an active and relatively non-toxic combination in advanced NSCLC.
- Trial name
- NCT00193427
- Testing
- Docetaxel, Gemcitabine, Carboplatin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- SCRI Development Innovations, LLC
Non-Small Cell Lung Cancer
Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
A randomized phase II trial to assess the efficacy and safety of selective metabolically adaptive radiation dose escalation in locally advanced non-small cell lung cancer receiving definitive chemoradiotherapy.
- Trial name
- PET-BOOST (NCT02788461)
- Testing
- Chemoradiotherapy, Chemoradiotherapy with Integrated Boost Dose
- Where
- 7 sites in Canada
- Volunteers
- 78 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Resectable Non-small Cell Lung Cancer, Bispecific Antibody
Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study
The advent of immunotherapy has changed the treatment landscape for patients with non-small cell lung cancer. It has become the mainstay of perioperative treatment for patients with resectable non-small cell lung cancer。…
- Conditions
- Resectable Non-small Cell Lung Cancer, Bispecific Antibody, Neoadjuvant Therapy
- Trial name
- Neoadjuvant (NCT06946836)
- Testing
- AK104
- Volunteers
- 80 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-Small Cell Lung Cancer, Breast Cancer
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
This is a Phase 1b/2, multi-center study to assess the safety and efficacy of ibrutinib in combination with durvalumab (MEDI4736) in participants with relapsed or refractory solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- NCT02403271
- Testing
- Ibrutinib, Durvalumab
- Where
- 17 sites in United States
- Volunteers
- 124 people
- Sponsor
- Pharmacyclics LLC.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.